durvalumab placebo

DRUG2 trials

Conditions

Advanced Ovarian CancerEndometrial Neoplasms

Phase 3

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Active, not recruitingNCT03737643

AstraZenecaAdvanced Ovarian Cancer

Start: 2019-01-04End: 2026-12-23Updated: 2026-07-07

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Active, not recruitingNCT04269200

AstraZenecaEndometrial Neoplasms

Start: 2020-05-05End: 2027-04-01Updated: 2026-08-07

2025-12-09

Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer.

2025-10-01

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.

2025-07-01

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA.

Journal of Clinical Oncology2025-05-287 citations

Real-world patient characteristics and survival outcomes in patients with advanced or recurrent endometrial cancer in England: a retrospective, population-based study

BMJ Open2024-11-011 citations

PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

British Journal of Cancer2024-07-0617 citations

Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by <i>BRCA1</i>/<i>BRCA2</i> mutation (BRCAm) status.

Journal of Clinical Oncology2024-06-012 citations

Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.

Journal of Clinical Oncology2024-06-011 citations

619 Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: results from the phase III DUO-E/GOG-3041/ENGOT-EN10 Trial

2024-03-011 citations

Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.

2024-02-2984 citations

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4

Nature Communications2023-09-0621 citations

#1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial

2023-09-012 citations

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.

Journal of Clinical Oncology2023-06-0750 citations

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.

2023-03-1518 citations

Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer

Scientific Reports2021-06-016 citations

DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).

Journal of Clinical Oncology2020-05-208 citations

DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.

Journal of Clinical Oncology2019-05-2046 citations

durvalumab placebo

Sponsors

Conditions

Phase 3

Related Papers